Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone
Background: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat, was first reported in 1999 and linked to anti...
Saved in:
Main Authors: | Atilla Büyükgebiz, And Demir |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Children |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9067/12/1/58 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial
by: Fumio Otsuka, et al.
Published: (2025-02-01) -
Short-acting growth hormone supplementation for bone age and growth rate in children with idiopathic short stature: a meta-analysis
by: Lianlian Yang, et al.
Published: (2025-01-01) -
GH Therapy in Non–Growth Hormone-Deficient Children
by: Chiara Guzzetti, et al.
Published: (2024-12-01) -
Comparison of growth hormone therapy response according to the presence of growth hormone deficiency in children born small for gestational age with short stature in Korea: a retrospective cohort study
by: Ha Young Jo, et al.
Published: (2025-02-01) -
Enhanced effect of the immunosuppressive soluble HLA-G2 homodimer by site-specific PEGylation
by: Chisato Yamada, et al.
Published: (2025-01-01)